Inside the research
ResMed Inc.
RMD Research profile · latest available data
Price overview
$222.00
▲ +0.11 (+0.0%)
| 52w hi | $280.31 |
|---|---|
| 52w lo | $182.30 |
| Vol | 760.80K |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.19
| Short | +0.01 |
|---|---|
| Medium | +0.29 |
| Long | +0.33 |
computed 2026-09-27
Key fundamentals
ResMed Inc.
Healthcare · Medical Instruments & Supplies
| Market cap | $32.02B |
|---|---|
| Enterprise value | $31.38B |
| Trailing P/E | 21.28x |
| Forward P/E | 16.78x |
| EV / EBITDA | 14.97x |
| P / S (ttm) | 5.66x |
| Profit margin | 26.9% |
| Return on equity | 24.3% |
| Revenue growth | +8.6% |
| Earnings growth | +2.4% |
| Debt / equity | 12.54 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.26 | |
| Sector | +0.08 | |
| Technical | +0.04 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Risk Metrics
| Beta vs SPX | 0.59 |
|---|---|
| Corr SPX | 0.33 |
| Annual vol | 28.2% |
| Annual ret | -0.9% |
| Sharpe | -0.03 |
| Max DD | -37.8% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $270.60 |
|---|---|
| High / Low | $340.00 / $180.00 |
| Median | $286.00 |
| Analysts | 15 |
| Strong Buy | 3 | |
|---|---|---|
| Buy | 8 | |
| Hold | 7 | |
| Sell | 1 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-01 | Wells Fargo | → Equal-Weight |
| 2026-05-01 | RBC Capital | → Outperform |
| 2026-04-27 | Keybanc | → Overweight |
| 2026-04-09 | Citigroup | → Buy |
| 2026-02-02 | Citigroup | → Buy |
| 2026-01-30 | Wells Fargo | → Equal-Weight |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-06 | Earnings Release, Other Material Event… | read |
| 2026-07-07 | Earnings Release, Reg FD Disclosure… | read |
| 2026-04-30 | Officer / Director Change, Exhibits | read |
| 2026-04-30 | Earnings Release, Other Material Event… | read |
| 2026-01-29 | Earnings Release, Other Material Event… | read |
| 2025-11-20 | Officer / Director Change, Shareholder Vote… | read |
| 2025-10-30 | Earnings Release, Other Material Event… | read |
| 2025-08-18 | Officer / Director Change, Exhibits | read |
| 2025-08-01 | Officer / Director Change | read |
| 2025-07-31 | Earnings Release, Other Material Event… | read |
| 2025-04-23 | Earnings Release, Other Material Event… | read |
| 2025-01-30 | Earnings Release, Other Material Event… | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-07 | Farrell Michael J. | Chairman and CEO | Option exercise | 4.99K | $730.38K |
| 2026-08-07 | Farrell Michael J. | Chairman and CEO | Sell | 4.99K | $1.03M |
| 2026-08-05 | FARRELL PETER C | Sell | 8.00K | $1.80M | |
| 2026-07-07 | Farrell Michael J. | Chairman and CEO | Option exercise | 4.99K | $730.38K |
| 2026-07-07 | Farrell Michael J. | Chairman and CEO | Sell | 4.99K | $1.09M |
| 2026-06-08 | Farrell Michael J. | Chairman and CEO | Option exercise | 4.99K | $730.38K |
| 2026-06-08 | Farrell Michael J. | Chairman and CEO | Sell | 4.99K | $968.06K |
| 2026-06-01 | Rider Michael J | Global General Counsel | Withheld for tax | 269 | $51.21K |
| 2026-05-07 | Farrell Michael J. | Chairman and CEO | Option exercise | 4.99K | $730.38K |
| 2026-05-07 | Farrell Michael J. | Chairman and CEO | Sell | 4.99K | $1.04M |
Flow & Concentration
| Insider 180d net | -$7.72M |
|---|---|
| Insider buys / sells | 0 / 8 |
| Insider bias | Sellers |
| 13F holders | 9 |
| Top-5 share | 97.1% |
| HHI | 4,747 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $1.30B | 6.68M |
| Capital Research / Capital World | $251.53M | 1.29M |
| AQR Capital Management | $177.14M | 910.62K |
| Citadel Advisors | $118.97M | 610.48K |
| Millennium Management | $46.17M | 236.93K |
| Fidelity / FMR LLC | $42.22M | 216.63K |
| Bridgewater Associates | $13.13M | 67.38K |
| Renaissance Technologies | $315.71K | 1.62K |
| T. Rowe Price Group | $72.43K | 371.66K |
As of 2026-06-30
Dividends
| Yield (TTM) | 0.54% |
|---|---|
| $ / share (TTM) | $1.20 |
| 5y CAGR | +7.7% |
Annual dividend per share
| 2021 | $1.62 |
|---|---|
| 2022 | $1.72 |
| 2023 | $1.84 |
| 2024 | $2.02 |
| 2025 | $2.26 |
| 2026 | $0.60 |
SEC Filings
The Long Run
FY 2011–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $5.15B | +10.7% | |
| Gross profit | $2.36B | +9.6% | |
| Operating income | $1.32B | +14.8% | |
| Net income | $1.02B | +12.8% | |
| Cash from ops | $1.40B | +19.4% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $221.08 | $223.22 | $220.13 | $222.00 | 760.80K |
| Sep 24 | $223.08 | $224.50 | $220.39 | $221.89 | 798.80K |
| Sep 23 | $222.78 | $225.10 | $220.00 | $222.30 | 1.44M |
| Sep 22 | $226.22 | $227.90 | $221.82 | $221.97 | 1.03M |
| Sep 21 | $225.16 | $226.52 | $223.34 | $223.61 | 1.07M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →